anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive 1.5 ounces of pistachios to consume every day for 6 months. We will provide them a 3-month supply of pistachios, and they will receive another 3-month supply when they come in for their 3-month study visit (blood draw).
This study was randomized clinical trial and was conducted in Pakistan Sports Board in duration of 10 months. Non-probability convenient sampling technique was used. Sample size was 30 calculated by G-power using 50-m sprint as variable. Participants were recruited into 2 equal groups by the process of randomization according to inclusion and exclusion criteria. One group performed mud based plyometric jump training with high intensity interval training which included alternate jump lunge, split squat jump and pop squat jump 4 repetitions, 3 sets and other performed mud based plyometric jump training without high intensity interval training which included plate pogo and broad jump 4 REPS, 3 SETS. Data was analyzed by SPSS version 25.
Table 1 summarizes the recommended dosages of SEPTOCAINE administered by intraoral submucosal infiltration or nerve block for various types of anesthetic dental procedures in healthy adults and pediatric patients.

The recommended dosages of SEPTOCAINE in healthy adults serve only as a guide to the amount of anesthetic required for most routine dental procedures. The dosages to be used in adults depend on several factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, administer the lowest dosage that will produce the desired result.  
The dosages of SEPTOCAINE to be used in pediatric patients aged 4 to 16 years old are determined by the age and weight of the patient and the type of dental procedure.  
For most routine dental procedures, SEPTOCAINE containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, SEPTOCAINE containing epinephrine 1:100,000 may be used.  
The onset of anesthesia and the duration of anesthesia are proportional to the dosage of the local anesthetic used. Exercise caution when employing large volumes because the incidence of adverse reactions may be dose-related.
Colorectal polyps are one of the precancerous lesions of colorectal cancer, 60-80% of which eventually become advanced colorectal cancer. Therefore, early resection of colorectal polyps can effectively reduce the incidence of colorectal cancer. Polyps under white light are judged mainly according to the shape, size and color of polyps. At present, the Paris classification is often used to divide 0-I uplifted polyps into sessile polyps (0-Is), sessile-pedunculated polyps (0-Isp) and pedunculated polyps (0-Ip). It is generally believed that there are thick arteries in 0-Ip polyps, especially thick pedunculated polyps, which are prone to uncontrollable bleeding during operation. 0-Is polyps have small scattered blood vessels and low intraoperative bleeding risk, while the morphological and structural characteristics of 0-Isp polyps are between the two. The current guidelines recommend HSP for 0-Isp and 0-Ip polyps \<1 cm, but the internal blood vessels of these polyps are not thick. There is no guidance on whether they can be resected by CSP method, and there is a lack of prospective large sample clinical research. This study will include0-Isp /0-Ip polyps \<1cm, and observe the safety and effectiveness of CSP for the above polyp resection , so as to provide reference for the clinical treatment of colorectal polyps.
FIELD: medicine. SUBSTANCE: method involves sequentially or at the same time exposing the concretion to shock waves of distant lithotripsy apparatuses and sterile litholytic mixture for destroying the calculi in kidneys or ureter into fragments of various sizes and shapes that are solved within 5-16 h completely under continuous action of the sterile litholytic mixture. The litholytic mixture has 400 ml of 5% glucose solution with 5000 units of heparin + 20 ml of 3.66% trisamine solution +400 ml of 0.2 % xidiphon solution in 0.9% sodium chloride solution. Transcutaneous laser radiation therapy is applied in severe cases above the femoral artery in the area of inguinal fold. EFFECT: enhanced effectiveness of treatment; accelerated treatment course. 3 cl
Waitlist control. This arm will receive psilocybin after the waiting period is over (20mg in first session and then, if well tolerated, 30mg).
At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score \<=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
PURPOSE: To easily obtain a pilosinine deriv. which can be used as a precursor of pilocarpine having pharmaceutical effects such as perspiration, stimulation on parasympathetic nervous system and miotic effect, from an easily available starting substance without by-products with high yield.  
     CONSTITUTION: A compd. expressed by formula I (R 1  is a 1 to 6 C straight-chain or branched alkyl) is allowed to react with a substd. or unsubstd. thiophenol, alkanethiol or alkenethiol under refluxing conditions to convert into a new substance expressed by formula II (R 2 , R 3  are each a 1 to 5 C alkyl, substd. or unsubstd. phenyl or benzyl, R 2  and R 3  may form a 1 to 5 C alkylene). Then the obtd. substance is subjected to deprotonation in the presence of a base, preferably an org. alkali metal compd., and to the reaction with γ-crotonolactone to obtain a new substance expressed by formula III. Moreover, preferably the new substance is reduced by using a hydrogenated multimetal compd. (such as LiAlH 4 , NaB 2 H 7 ) or Raney nickel to advantageously obtain a pilosinine deriv. expressed by formula IV with high yield. 
     COPYRIGHT: (C)1993,JPO
Aerobic Exercises include walk for 50 min with the frequency of 3 days per week. This exercise will be done for a 6-week period.
The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
Study 4 (NCT 01892722) evaluated the efficacy of once-daily oral doses of GILENYA 0.25 mg or GILENYA 0.5 mg in pediatric patients 10 to less than 18 years of age with relapsing-remitting multiple sclerosis. Study 4 was a 215-patient, double-blind, randomized, clinical trial that compared GILENYA to intramuscular interferon beta-1a. Prior therapy with interferon-beta, dimethyl fumarate, or glatiramer acetate up to the time of randomization was permitted. The study included patients who had experienced at least 1 clinical relapse during the year prior or 2 relapses during the 2 years prior to screening, or evidence of 1 or more Gd-enhancing lesions on MRI within 6 months prior to randomization, and had an EDSS score from 0 to 5.5. Neurological evaluations were scheduled at screening, every 3 months, and at the time of suspected relapses. MRI evaluations were performed at screening and every 6 months throughout the study. The primary endpoint was the annualized relapse rate.

At baseline, the median age was 16 years, median disease duration since first symptom was 1.5 years, and median EDSS score was 1.5. One patient received no study drug and is excluded from the analysis of efficacy. Median duration of exposure to study drug was 634 days in the GILENYA group (n = 107) and 547 days in the interferon beta-1a group (n = 107). In the GILENYA group, 6.5% of patients did not complete the study, compared to 18.5% in the interferon beta-1a group.

The primary endpoint, the annualized relapse rate (ARR), was significantly lower in patients treated with GILENYA (0.122) than in patients who received interferon beta-1a (0.675). Relative reduction in ARR was 81.9%. The annualized rate of the number of new or newly enlarged T2 lesions up to Month 24 (key secondary endpoint) was significantly lower in patients treated with GILENYA, as was the number of Gd-enhancing T1 lesions per scan up to Month 24.

Table 4 summarizes the results of Study 4.
PURPOSE: To diagnose an onset of certain dementia such as AD, MID, ALS-PD and HD, preferably AD and MID, before appearance of clinical symptoms of the deseases by monitoring changes in relative concentrations of two types of albumin in serum or CSF. CONSTITUTION: Relative levels of normal albumin and variant alubumins in serum are assumed and traced as indicators about beginning and proceeding of certain dementia for a certain time. The figure shows a relationship between concentrations of albumin and immunoglobulin G concentrations in CSF (IgG) and an IgG index (respective indexes are the ratios of albumin and IgG in CSF in mg/l to those in serum in g/l). White symbols and black symbols express the values of average albumin and IgG, respectively. Data of albumin are expressed as C, A and M for control, AD and MID group, respectively. Laboratories in which data were obtained are expressed as 1, 2, 3, and 4. Albumin indexes and albumin concentrations in CSF agree very well for a substantially wide range of the index values.
There are common methods for removing carious portions of a tooth such as tooth extraction, grinding and removing with a hand piece. However, when the hand piece, rotating at high speeds, contacts a tooth, very strong impact and noise occur due to high hardness properties of the tooth; and the impact and the noise provide extreme physical and psychological pain to a patient. Therefore, a composition as the prior commercial product, which effectively removes carious portions of a decayed tooth by a chemical reaction without noise and pain, has been used. However, the prior commercial product uses NaOCl and amino acid as main ingredients, which may be ingredients harmful to a human body and flow into an oral cavity of a patient due to low viscosity thereof during treatment. In the present invention, diluted organic acid with low viscosity or calcium hypochloritea which is not harmful to a human body compared to the prior product is used as a pH adjuster; and a polyamino acid mixture, a polymer, is used. Therefore, the present invention provides: a dental cavity treating agent composition, which can easily remove calcium inorganic materials and collagen from a carious portion of a tooth, does not flow into an oral cavity due to high viscosity thereof during treatment, and is not harmful to a human body; and a method for producing the same.
Premenstrual syndrome (PMS) affects millions of women during their reproductive years. The disorder presents with emotional, cognitive, behavioural, and somatic symptoms during the final premenstrual phase and subsiding a few days after menses begins. About 75% of women of reproductive age experience a mild form of PMS (Campbell, Peterkin, O'Grady, \& Sanson-Fisher, 1997). The more severe form of PMS, premenstrual dysphoric disorder (PMDD; American Psychiatric Association (APA), 1994) is considered to affect up to 8% of women of reproductive age. This severe form is associated with severe disruptions in normal functioning in work, family, or social relationships (Halbreich, Borenstein, Pearlstein, \& Kahn, 2003). The defining characteristics of both-PMS and PMDD- are the cyclic pattern of symptoms, which must be confirmed by prospective daily self ratings of symptoms (PMS-Diary) over two consecutive menstrual cycles (American College of Obstetricians and Gynecologists (ACOG), 2000). PMS and PMDD differ according to the number, severity, duration, and quality of symptoms.

As a first-line intervention, the ACOG suggests pharmacotherapy, in particular selective serotonin reuptake inhibitors (SSRIs; ACOG, 2000). However, the side effects of SSRIs are intolerable to many women, leading to high rates of withdrawal from treatment (Busse et al., 2009; Dimmock, Wyatt, Jones, \& O'Brien, 2000). Thus, cognitive behavioural treatments (CBT) have been suggested as an additional treatment approach (Busse et al., 2009). First studies showed promising results for CBT interventions for PMS (Busse et al., 2009; Hunter et al., 2002). However, too few randomized controlled trials have carefully investigated the efficacy of CBT for PMS.

The aim of the current study is thus to develop a CBT-oriented self-help treatment programme for women suffering from PMS or PMDD. The treatment programme consists of psychoeducation (e.g., information about PMS/PMDD and its aetiology), cognitive strategies (e.g., assessing and restructuring dysfunctional cognitions), and suggestions for lifestyle changes (e.g., sports, balanced diet, relaxation). The programme is internet-delivered (iCBT) and participants work on different chapters for eight weeks in a row. In addition to written information, participants receive e-mail feedback from a psychologist on a weekly basis. Participants are required to have sufficient knowledge of German in order to be able to read the treatment materials. After a careful diagnostic assessment (including two months symptom diary), eligible patients are randomly assigned either to the treatment group or a waitlist control group. Participants assigned to the waitlist receive the treatment after the end of the waiting period (eight weeks). Follow-up assessments take place six months after the end of the treatment.
Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
Participants will be placed on a low-calorie diet regimen consisting of \~1,300 kcal/day (55% carbohydrates, 13% fat, 25% protein, and 2% fiber) over 8 weeks. They will receive weekly pre-prepared meals (breakfast, lunch, and dinner) meticulously crafted by certified dieticians and expert chefs. Participants will be instructed to store the meals in the fridge or freezer and heat them using an air fryer, oven, microwave, or stovetop. They will be encouraged to consume 1-2 liters of water daily and maintain their habitual physical activity levels. A weight loss goal of at least 10% is set for the participants. Upon completion of the 8-week intervention, participants will transition back to their habitual dietary patterns while receiving guidance on portion sizes and healthy eating practices.
TRIAL / STUDY DESIGN Each participant will be required to attend a screening visit, a brief education visit re collecting dietary information, adhering to a standardised diet and faecal sample collection; two, approximately five hour, study visits with 7- 10 days between each visit; and a brief visit after each intervention day to return diet information and the faecal samples. Prior to the study visits they will be required to consume a standardised diet for four days, based on their usual intake with similar macronutrient composition to the feed. On each study visit they will be fed, via a nasogastric enteral tube, 300mls/ hour of one of two enteral feeds (total feed delivered 300mls). The gastric response will be measured using MRI scanning, the biochemical and endocrine response will be measured using arterialised venous blood samples, and the appetitive response will be measured using visual analogue scales, and direct measurement of food intake at an ad libitum test meal. Participants will continue to consume a standardised diet for 3 days after the delivery of the enteral feed. Faecal samples will be collected before and after the visit day, for pH measurement.

Ethical approval has been obtained from the Faculty of Medicine and Health Sciences Ethics Committee, University of Nottingham. All participants will provided informed, written consent.
Advise all patients to hydrate adequately before, during, and after the use of SUPREP Bowel Prep Kit. If a patient develops significant vomiting or signs of dehydration after taking SUPREP Bowel Prep Kit, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN).

Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with SUPREP Bowel Prep Kit. Use SUPREP Bowel Prep Kit with caution in patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions ( 7.1)] . 

SUPREP Bowel Prep Kit can cause temporary elevations in uric acid [see Adverse Reactions ( 6.1)] . Uric acid fluctuations in patients with gout may precipitate an acute flare. The potential for uric acid elevation should be considered before administering SUPREP Bowel Prep Kit to patients with gout or other disorders of uric acid metabolism.
OBJECTIVE: The aim of this research was to examine how penehyclidine hydrochloride (PHC) impacts the occurrence of pyroptosis in lung tissue cells within a rat model of lung ischemia-reperfusion injury.
METHODS: Twenty-four Sprague Dawley (SD) rats, weighing 250 g to 270 g, were randomly distributed into three distinct groups as outlined below: a sham operation group (S group), a control group (C group), and a test group (PHC group). Rats in the PHC group received a preliminary intravenous injection of PHC at a dose of 3 mg/kg. At the conclusion of the experiment, lung tissue and blood samples were collected and properly stored for subsequent analysis. The levels of malondialdehyde, superoxide dismutase, and myeloperoxidase in the lung tissue, as well as IL-18 and IL-1β in the blood serum, were assessed using an Elisa kit. Pyroptosis-related proteins, including Caspase1 p20, GSDMD-N, and NLRP3, were detected through the western blot method. Additionally, the dry-to-wet ratio (D/W) of the lung tissue and the findings from the blood gas analysis were also documented.
RESULTS: In contrast to the control group, the PHC group showed enhancements in oxygenation metrics, reductions in oxidative stress and inflammatory reactions, and a decrease in lung injury. Additionally, the PHC group exhibited lowered levels of pyroptosis-associated proteins, including the N-terminal segment of gasdermin D (GSDMD-N), caspase-1p20, and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3).
CONCLUSION: Pre-administration of PHC has the potential to mitigate lung ischemia-reperfusion injuries by suppressing the pyroptosis of lung tissue cells, diminishing inflammatory reactions, and enhancing lung function. The primary mechanism behind anti-pyroptotic effect of PHC appears to involve the inhibition of oxidative stress.
PURPOSE:To obtain a prophylactic and therapeutic agent for an intimal hypertrophy of artery, particularly useful for a prophylaxis and therapy of a coronary restenosis after PTCA, having less adverse effect, containing 3- phenylthiomethylstyrene derivative as an effective component. CONSTITUTION:This agent contains a compound or its salt of formula (X is H, an alkoxy, a 1-5C alkyl, nitro, etc.; R<1> is H, a 1-3 alkyl or an acyl; R<2> is Hor a 1-5C alkyl; R' is an amide, etc.; R<4> is cyano, an alkylsulfonyl, etc.; n is 1-5; m is 0-3). The compound of the formula having effects of anti-allergic, antitumor and tyrosine kinase inhibition, is useful in prophylaxis and treatment of an atherosclerosis, a restenosis after a percutaneous transluminal coronary angoiplasty (PTCA) and in prophylaxis and treatment of an intimal hypertrophy of artery accompanying to an indwelling stent. Its single dosage is 1-1000mg/kg, and its daily dosage is 20-4000mg/kg.
The 120z Dual-Channel TENS Unit (ECS300A; Neurotrac, Verity Medical LTD, Ireland) will be used to stimulate the selected acupoints. The electrode will be placed over the acupoints and connected to the TENS stimulator. The stimulation frequency will be set at 100 Hz with a pulse width of 0.2 ms. Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
Pheochromocytoma and Neuroblastoma

Begin whole body planar scintigraphy imaging 24 ± 6 hours following administration of AdreView. Single photon emission computed tomography (SPECT) may be performed following planar scintigraphy, as appropriate [see Clinical Studies (14.1)].

Congestive Heart Failure

Begin anterior planar imaging of the chest at 4 hours (± 10 minutes) following administration of AdreView. Single photon emission computed tomography (SPECT) can then be performed. The recommended collimator for all imaging is a low-energy high-resolution. The recommended matrix for planar images is 128×128. The camera should be positioned to include the entire heart and as much of the upper chest as possible within the field of view [see Clinical Studies (14.2)].
OBJECTIVES: The indications and modalities of breast and axillary surgery are undergoing profound change, with the aim of personalizing surgical management while avoiding over-treatment. To update best practices for axillary surgery, four questions were selected by the Senology Commission of the Collège National des Gynécologues et Obstétriciens Français (CNGOF), focusing on, firstly, the definition and evaluation of targeted axillary dissection (TAD) techniques; secondly, the possibility of surgical de-escalation in case of initial lymph node involvement while performing initial surgery; thirdly, in case of surgery following neo-adjuvant systemic therapy (NAST), and fourthly, contra-indications to de-escalation of axillary surgery to allow access to particular adjuvant systemic therapies.
METHODS: The Senology Commission based its responses primarily on an analysis of the international literature, clinical practice recommendations and national and international guidelines.
RESULTS: Firstly, TAD is a technique that combines excision of clipped metastatic axillary node(s) and the axillary sentinel lymph nodes (ASLNs). The detection rate and sensitivity are increased but it still needs to be standardized and practices better evaluated. Secondly, TAD represents an alternative to axillary clearance in cases of metastatic involvement of a single node that can be resected. Thirdly, neither TAD nor ASLN alone is recommended in France after NAST outside of clinical trials, although it is used in several countries in cases of complete pathological response in the lymph nodes, and when at least three lymph nodes have been removed. Fourthly, as some adjuvant targeted therapies are indicated in cases of lymph node invasion of more than three lymph nodes, the place of TAD in this context remains to be defined.
CONCLUSION: Axillary surgical de-escalation can limit the morbidity of axillary clearance. Having proved that TAD does not reduce patient survival, it will most probably replace axillary clearance in well-defined indications. This will require prior standardization of the method and its indications and contra-indications, particularly to enable the use of new targeted therapies.